Effect of Once‐Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants
The Journal of Clinical Pharmacology · 2026-04 · 66 (4)
DOI: 10.1002/jcph.70185 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 23.04.2026. Verfasst von Dénes Csonka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Endothelin Receptor Antagonists, Pyrazoles, Pyrimidines, Rosuvastatin Calcium. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson and Johnson.
Abstract (Originalsprache)
Macitentan is an oral, dual ET A /ET B endothelin receptor antagonist, currently approved in adults for the treatment of pulmonary arterial hypertension (PAH) at a once‐daily dose of 10 mg. Pre‐clinical and clinical data suggest that greater ET B receptor inhibition may result in greater efficacy. This hypothesis is being tested in the Phase 3 UNISUS study (NCT04273945), comparing once‐daily macitentan 75 mg versus macitentan 10 mg. The present Phase 1 study (NCT04211272) evaluated the pharmacokinetics and safety of concomitant administration of once‐daily macitentan 75 mg at steady state with substrates of either breast cancer resistance protein (BCRP) transporter (e.g., riociguat and rosuvastatin) or cytochrome P450 3A4 (CYP3A4) enzymes (e.g., sildenafil and tadalafil) in healthy male adults. Macitentan was administered once daily at 10 mg on Days 1 and 2, 37.5 mg on Days 3‐5, and 75 mg on Days 6‐13. Participants received a single oral dose of sildenafil (20 mg) on Days −4 and 13, riociguat (1 mg) on Days −3 and 10, or rosuvastatin (10 mg) on Days −4 and 10. Geometric mean ratios for the maximum concentration and area under the curve of the substrate and 90% confidence intervals showed no clinically relevant effects on exposure for sildenafil, riociguat, or rosuvastatin when administered alone or with macitentan 75 mg. Co‐administration of macitentan and the substrates was generally well tolerated. Due to the lack of clinically relevant drug–drug pharmacokinetic interactions, no dose adjustment is deemed necessary when co‐administering once‐daily macitentan 75 mg with BCRP or CYP3A4 substrates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johnson & Johnson, Allschwil, Switzerland.
- Johnson and Johnson, Spring House, PA, USA.
- Johnson & Johnson, Raritan, NJ, USA.
- Johnson & Johnson, Beerse, Belgium.
Förderung
- Johnson and Johnson
Zitieren
APA
Csonka, D., Gargano, C., Goyal, N., De Meulder, M., Yartsev, V., & Ruixo, J. J. P. (2026). Effect of Once‐Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. The Journal of Clinical Pharmacology, 66(4). https://doi.org/10.1002/jcph.70185
Vancouver
Csonka D, Gargano C, Goyal N, De Meulder M, Yartsev V, Ruixo JJP. Effect of Once‐Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. The Journal of Clinical Pharmacology. 2026;66(4). doi:10.1002/jcph.70185
BibTeX
@article{Csonka2026,
author = {Csonka, Dénes and Gargano, Cynthia and Goyal, Navin and De Meulder, Marc and Yartsev, Vitaly and Ruixo, Juan Jose Perez},
title = {Effect of Once‐Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {4},
doi = {10.1002/jcph.70185}
}
EUVIMED